GlassScriptPhysician profile
Franz J Stadler
NPI 1578566873
$3,853.50
in general payments reported to CMS, 2019-2025
26 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $221 · 2022: $232 · 2023: $592 · 2024: $1,393 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.57 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $370.97 | 2022-2024 | Taltz, Olumiant, Zepbound |
| Sun Pharmaceutical Industries INC. | $343.26 | 2020-2025 | Ilumya |
| Genzyme Corporation | $336.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.69 | 2024-2025 | Dupixent, Libtayo |
| Edwards Lifesciences Corporation | $215.24 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal |
| Novartis Pharmaceuticals Corporation | $189.37 | 2022-2025 | |
| Leo Pharma INC. | $187.27 | 2019-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $171.86 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $113.86 | 2023-2024 | Sotyktu |
| Pfizer INC. | $111.40 | 2023-2024 | |
| Ucb, INC. | $74.30 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.94 | 2023-2025 | Jublia |
| Incyte Corporation | $69.42 | 2023-2025 | Opzelura |
| Amgen INC. | $67.75 | 2019-2025 | Otezla, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $60.48 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $59.60 | 2022-2025 | |
| Organogenesis INC. | $40.41 | 2019-2020 | |
| Janssen Biotech, INC. | $39.03 | 2025 | Tremfya |
| Vyne Pharmaceuticals INC. | $34.77 | 2020 | |
| Botanix Sb INC | $29.53 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $28.52 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.67 | 2023 | Spevigo |
| Dusa Pharmaceuticals, INC. | $19.93 | 2019 | |
| Merck Sharp & Dohme LLC | $18.83 | 2019 | |
| Organon LLC | $17.73 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franz Stadler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.